Minocycline Hydrochloride (Minocycline Hydrochloride)

Trade Name : Minocycline Hydrochloride

Teva Pharmaceuticals USA, Inc.

TABLET, FILM COATED, EXTENDED RELEASE

Strength 115 mg/1

MINOCYCLINE HYDROCHLORIDE Tetracycline-class Drug [EPC],Tetracyclines [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Minocycline Hydrochloride (Minocycline Hydrochloride) which is also known as Minocycline Hydrochloride and Manufactured by Teva Pharmaceuticals USA, Inc.. It is available in strength of 115 mg/1 per ml. Read more

Minocycline Hydrochloride (Minocycline Hydrochloride) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Minocycline Hydrochloride Extended-release Tablets are a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. ()
  • The recommended dosage of minocycline hydrochloride extended-release tablets is approximately 1 mg/kg once daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.
  • The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.
  • Minocycline hydrochloride extended-release tablets may be taken with or without food []. Ingestion of food along with minocycline hydrochloride extended-release tablets may help reduce the risk of esophageal irritation and ulceration.
  • In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses [].
  • The recommended dosage of minocycline hydrochloride extended-release tablets is approximately 1 mg/kg once daily for 12 weeks. ()
  • Extended release tablets:u00a0 55, 65, 80, 105 and 115 mg ()
  • This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
  • This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. ()
  • No data
  • The use of minocycline hydrochloride extended-release tablets during tooth development (last half of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). ()
  • If pseudomembranous colitis occurs, discontinue minocycline hydrochloride extended-release tablets. ()
  • If liver injury is suspected, discontinue minocycline hydrochloride extended-release tablets. ()
  • If renal impairment exists, minocycline hydrochloride extended-release tablets doses may need to be adjusted to avoid excessive systemic accumulations of the drug and possible liver toxicity. ()
  • Minocycline may cause central nervous system side effects including light-headedness, dizziness, or vertigo. Advise patients. ()
  • Minocycline may cause pseudotumor cerebri (benign intracranial hypertension) in adults and adolescents. Discontinue minocycline hydrochloride extended-release tablets if symptoms occur. ()
  • Minocycline has been associated with autoimmune syndromes; discontinue minocycline hydrochloride extended-release tablets immediately if symptoms occur. ()
  • Minocycline has been associated with anaphylaxis, serious skin reactions, erythema multiforme, and DRESS syndrome. Discontinue minocycline hydrochloride extended-release tablets immediately if symptoms occur. ()
  • The most commonly observed adverse reactions (incidence u2265 5%) are headache, fatigue, dizziness, and pruritus. ()
  • To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
  • No data
  • Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ()
  • The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ()
  • To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with minocycline. ()
  • No data
  • Minocycline like other tetracycline-class drugs can cause fetal harm when administered to a pregnant woman (, )
  • The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of teeth (, )
  • In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.
  • Minocycline hydrochloride, USP, a semi synthetic derivative of tetracycline, is [4(4u03b1,4au03b1,5au03b1,12au03b1)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structural formula is represented below:
  • CHNOu2022HClu00a0 u00a0M.W. 493.95
  • Minocycline Hydrochloride Extended-release Tablets USP for oral administration contain minocycline hydrochloride, USP equivalent to 55 mg, 65 mg, 80 mg, 105 mg or 115 mg of minocycline.u00a0 In addition, 55 mg, 65 mg, 80 mg, 105 mg and 115 mg tablets contain the following inactive ingredients: carnauba wax, colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, titanium dioxide and triacetin.u00a0 The 55 mg tablets also contain iron oxide red; the 65 mg tablets also contain D&C red no. 27 aluminum lake, FD&C blue no. 2 aluminum lake and FD&C red no. 40 aluminum lake; the 105 mg tablets also contain iron oxide yellow, iron oxide red and iron oxide black; the 115 mg tablets also contain D&C yellow no. 10 aluminum lake and FD&C blue no. 2 aluminum lake.
  • No data
  • Carcinogenesis
  • Mutagenesis
  • in vitro
  • in vitro
  • in vivo
  • Impairment of Fertility
  • Limited human studies suggest that minocycline may have a deleterious effect on spermatogenesis.
  • Minocycline hydrochloride extended-release tablets should not be used by individuals of either gender who are attempting to conceive a child.
  • The safety and efficacy of minocycline hydrochloride extended-release tablets in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris was assessed in two 12-week, multi-center, randomized, double-blind, placebo-controlled, trials in subjects u2265 12 years. The mean age of subjects was 20 years and subjects were from the following racial groups: White (73%), Hispanic (13%), Black (11%), Asian/Pacific Islander (2%), and Other (2%).
  • In two efficacy and safety trials, a total of 924 subjects with non-nodular moderate to severe acne vulgaris received minocycline hydrochloride extended-release tablets or placebo for a total of 12 weeks, according to the following dose assignments.
  • The two primary efficacy endpoints were:
  • 1) Mean percent change in inflammatory lesion counts from Baseline to 12 weeks.
  • 2) Percentage of subjects with an Evaluatoru2019s Global Severity Assessment (EGSA) of clear or almost clear at 12 weeks.
  • Efficacy results are presented in .n
  • u00a0
  • Minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory lesions (benefit or worsening).
  • No data
  • See FDA-approved patient labeling (Patient Labeling)
  • Patients taking minocycline hydrochloride extended-release tablets should receive the following information and instructions:
  • All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.
  • Teva Pharmaceuticals USA, Inc.
  • Rev. M 5/2019
  • Minocycline (min'' oh sye' kleen)
  • Hydrochloride (hye'' droe klor' ide)
  • Extended-release Tablets
  • Read this Patient Information leaflet that comes with minocycline hydrochloride extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.
  • What are minocycline hydrochloride extended-release tablets?
  • Minocycline hydrochloride is a tetracycline-class drug. Minocycline hydrochloride extended-release tablets are prescription medicine used to treat pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne vulgaris in people 12 years and older. Minocycline hydrochloride extended-release tablets are not effective for acne that is not red-looking (this means acne that is not inflammatory).
  • It is not known if minocycline hydrochloride extended-release tablets are:
  • Who should not take minocycline hydrochloride extended-release tablets?
  • Do not take minocycline hydrochloride extended-release tablets if you are allergic to tetracycline class drugs. Ask your doctor or pharmacist for a list of these medicines if you are not sure.
  • What should I tell my doctor before taking minocycline hydrochloride extended-release tablets?
  • Before you take minocycline hydrochloride extended-release tablets, tell your doctor if you:
  • Tell your doctor about all the other medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements.
  • Especially tell your doctor if you take:
  • Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above. Know the medicines you take. Keep a list of them to show your doctor and pharmacist.
  • How should I take minocycline hydrochloride extended-release tablets?
  • If you take too much minocycline hydrochloride extended-release tablets, call your doctor or poison control center right away.
  • What should I avoid while taking minocycline hydrochloride extended-release tablets?
  • What are possible side effects of minocycline hydrochloride extended-release tablets?
  • Minocycline hydrochloride extended-release tablets may cause serious side effects, including:
  • The most common side effects of minocycline hydrochloride extended-release tablets include:
  • Call your doctor if you have a side effect that bothers you or that does not go away. Your doctor may do tests to check you for side effects during treatment with minocycline hydrochloride extended-release tablets.
  • These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask your doctor or pharmacist for more information.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Teva Pharmaceuticals USA, Inc. at 1-888-838-2872.
  • How should I store minocycline hydrochloride extended-release tablets?
  • Keep minocycline hydrochloride and all medicines out of the reach of children.
  • General information about minocycline hydrochloride extended-release tablets
  • Medicines are sometimes prescribed for purposes other than those listed in the patient information leaflet. Do not use minocycline hydrochloride extended-release tablets for a condition for which they were not prescribed. Do not give minocycline hydrochloride extended-release tablets to other people, even if they have the same symptoms you have. It may harm them.
  • This patient information leaflet summarizes the most important information about minocycline hydrochloride extended-release tablets. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about minocycline hydrochloride extended-release tablets that is written for health professionals.
  • For more information, call 1-888-838-2872.
  • What are the ingredients in minocycline hydrochloride extended-release tablets?
  • Active Ingredient:
  • Inactive Ingredients:
  • This patient information has been approved by the U.S. Food and Drug Administration.
  • All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.
  • Teva Pharmaceuticals USA, Inc.
  • Rev. M 5/2019n
  • NDCu00a00093-7741-56
  • Minocycline HCl Extended-release Tablets USP55 mg*
  • PHARMACIST: Dispense the accompanyingu00a0Patient Information Sheet to each patient.
  • Rx only
  • 30 TABLETS
  • TEVA
  • NDCu00a00093-2134-56
  • Minocycline HCl Extended-release Tablets USP65 mg*
  • PHARMACIST: Dispense the accompanyingu00a0Patient Information Sheet to each patient.
  • Rx only
  • 30 TABLETS
  • TEVA
  • NDCu00a00093-7742-56
  • Minocycline HCl Extended-release Tablets USP80 mg*
  • PHARMACIST: Dispense the accompanyingu00a0Patient Information Sheet to each patient.
  • Rx only
  • 30 TABLETS
  • TEVA
  • NDCu00a00093-7743-56
  • Minocycline HCl Extended-release Tablets USP105 mg*
  • PHARMACIST: Dispense the accompanyingu00a0Patient Information Sheet to each patient.
  • Rx only
  • 30 TABLETS
  • TEVA
  • NDCu00a00093-2133-56
  • Minocycline HCl Extended-release Tablets USP115 mg*
  • PHARMACIST: Dispense the accompanyingu00a0Patient Information Sheet to each patient.
  • Rx only
  • 30 TABLETS
  • TEVA

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Dossiers and Stability Studies

Dossiers and Stability Studies

STABILITY STUDIES STABILITY, BA / BE STUDIES Due to our active

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71247 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.